London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
One small caveat. If an EUA was attempted and off the back of that preorders arrived that would substantially change the picture but that’s putting the cart before the horse and we’re still in the stable with the doors locked
Lots of positive a but expectations of a sharp rise after ATS are a little presumptuous IMV.
The reality is we still have no approval or even attempt at an application for one. Even if we applied on Monday that process could take 6-8 months to reach a conclusion. We still don’t have a trial and even if one is announced next week it could take many months to set up, let alone run. Information about a PT next week May we’ll move the share upwards but it will be tempered by the reality of how long that road is likely to take. A sharper price rise would occur off the back of an attempt at an EUA but again the time frame to getting it granted or it being successful would hold a large rise back. It’s more likely a JV or TO would add value but they’re completely unknown to us at present. It’s a waiting game and it could be short or long. I just hope the board has more for us on one or more of those topics
Yes the results were astounding.... We should have seen a significant rise in the SP on the back of them.. The RNS did not do justice to the news and did not attract new investors... It is so disappointing to see we are only a few pence higher than last Friday... Investors pay the wages and fund the research...So our CEO needs to understand the importance of supporting them.... I thought we could see 80p when I read the RNS...Anyway I did communicate this to Brooke, and RM came across well in the Proactive interview, let's hope our update next week is upbeat and highlights our outstanding DATA...Or I will be going to the AGM.....LOL!!! ATB!
After this: "In these patients, who represented approximately one-third of the SPRINTER trial population, SNG001 significantly reduced the risk of progression to severe disease and death compared to placebo by 70% in the Per Protocol population (Odds Ratio (95% Confidence Interval) 0.23 (0.06, 0.98); p=0.046)"
They should have wriiten:
"This is most excellent!!! PARTY ON most excellent prospective investors".
They had a commercial plan in place before Feb 21st. EUA application written and ready to go - confident that a pre-order would follow. Plus the commercial hires and tested production pipeline. That all got washed away and I'd say that we don't really want a new plan yet. We were hoping DD and Activ 2 data would recover some of the value, before further announcements about the way forward. That - astonishingly to me - hasn't happened so far. As a consequence unless we get the A2 data and it's surprisingly good and/or the drug is confirmed as one of the FDA's new antiviral trialists I wouldn't be expecting anything from the AGM. Or at least I expect a reaffirmation that they're exploring platform trials and not much else. The market is bonkers though to not price in any of the potential of this bargain basment share.
Hi Size I disagree..If you have never invested in a pharma stock, then just reading % is not enough particularly on AIM...Especially when we are discussing results from a trial that failed... Most posters here understand the significance, but I imagine that many who saw the rise, sort out the RNS to understand what was behind it were not given enough information ( an explanation) to make a judgement on whether to invest or not! There was no hint in the RNS that the Board/Team were excited by the Data....But we all were!
Had RM added a few comments on how exciting the results are for SNG many more would have appreciated the % in the RNS... He said nothing.. A wasted opportunity to support investors... !! So undervalued here...IMHO!
“So a drug achieving a 70% reduction of progression to severe disease and death, in my opinion, is the holy grail result that we've been looking for - and we've achieved it in a sample size that was bigger than our P2 hospital arm”
My thoughts exactly especially after proving stastically significance. Hopefully the SP reflects these thoughts soon.
Thank you so much. It is so helpful to have an informed response. Thank you for taking the time to reply. For all the speculation from us armchair investors, nothing beats the perspective of someone who has their boots on the ground - either in hospitals, pharma or data. All looking good here. Thanks again.
Well the respiratory rate of a patient is the most helpful vital sign that tells us how unwell they are, hence why the respiratory rate assessment comes before the cardiovascular assessments like heart rate, heart sounds, capillary refill times and blood sugars - when we're doing a top to toe assessment of a clinically deteriorating patient. Those patients typically require the kitchen sink approach of rapid stabilisation and a lot of the time they escalate to higher intensity care settings with other teams getting involved if that doesn't work. Therefore, high resps can quickly tell us which people are going to go off and how quick we'd need to act. That applies to any clinical setting and not just on a respiratory ward. Whether it's Cardiology, Psychiatry or Geriatrics, respiratory compromise is an area that needs to be sorted pronto before doing anything else. Short of sticking somebody on 15L of oxygen and chest x-raying them in the unfortunate event that somebody does have respiratory compromise, you'd want to get a therapeutic into them too.
So a drug achieving a 70% reduction of progression to severe disease and death, in my opinion, is the holy grail result that we've been looking for - and we've achieved it in a sample size that was bigger than our P2 hospital arm.
xviolet - To put it in perspective, some of the other drugs that have been approved cut progression to severe disease or death by much less than that (the Arthritis drug Baricitinib was only 13%). See here...
If you've got a moment can you just re-confirm that the 70% over SOC is really special. I don't really understand the percentages and data - but you seemed very confident the data is now telling a very positive story. I assume you still feel that way. I only ask because the data is beyond me at the moment. I have to invest on price (buy cheap) to compensate for what I don't understand.